SynthesisPloS one2023
Long-term efficacy of mandibular advancement devices in the treatment of adult obstructive sleep apnea: A systematic review and meta-analysis.
Synthesis in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Effectiveness of mandibular advancement devices in obstructive sleep apnea therapy for East Asian patients: a systematic review and meta-analysis.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Pooled it
- Polygraphic evaluation of the effects of functional orthodontic treatment with twin block and herbst appliances on sleep quality: a randomized clinical trial.Sleep & breathing = Schlaf & Atmung · 2026Trial
- Individualized Treatment Approaches for Obstructive Sleep Apnea in Older Adults: Beyond Continuous Positive Airway Pressure.Advances in geriatric medicine and research · 2026Article
- Comparative effects of CPAP and mandibular advancement devices in obstructive sleep apnea: an overview of systematic reviews.Sleep & breathing = Schlaf & Atmung · 2026Review
- Mandibular Advancement Device Therapy in 182 DISE-Selected Adults with Moderate-to-Severe Obstructive Sleep Apnea: A Multicenter Real-World Study.Biomedicines · 2026Article
- CT and finite element analysis of mandibular advancement device mechanics in a participant with obstructive sleep apnea: a proof-of-concept study.BMC oral health · 2026Article
- The Natural History of Obstructive Sleep Apnea: A Scoping Review.Healthcare (Basel, Switzerland) · 2026Review
- Obstructive Sleep Apnea: The Expanding Role of Dental Sleep Medicine-A Systematic Review of Mandibular Advancement Devices, Treatment Efficacy, and Occlusal Complications.Dentistry journal · 2026Review
- "Characterization of Brazilian Dentistry in Dental Sleep Medicine".Sleep science (Sao Paulo, Brazil) · 2025Article
- Evaluating the effectiveness of mandibular advancement devices in treating very severe obstructive sleep apnea: a retrospective cohort study.Sleep & breathing = Schlaf & Atmung · 2025Article
- Sleep and periodontal health.Periodontology 2000 · 2024Review
- Obstructive sleep apnea: What is an orthodontist's role?Progress in orthodontics · 2024Review
- Home Respiratory Therapies in Patients With Obstructive Sleep Apnea: A Value-based Care Model in Spain.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to review the long-term subjective and objective efficacy of mandibular advancement devices (MAD) in the treatment of adult obstructive sleep apnea (OSA). Electronic databases such as PubMed, Embase, and Cochrane Library were searched. Randomized controlled trials (RCTs) and non-randomized self-controlled trials with a treatment duration of at least 1 year with MAD were included. The quality assessment and data extraction of the included studies were conducted in the meta-analysis. A total of 22 studies were included in this study, of which 20 (546 patients) were included in the meta-analysis. All the studies had some shortcomings, such as small sample sizes, unbalanced sex, and high dropout rates. The results suggested that long-term treatment of MAD can significantly reduce the Epworth sleepiness scale (ESS) by -3.99 (95%CI -5.93 to -2.04, p<0.0001, I2 = 84%), and the apnea-hypopnea index (AHI) -16.77 (95%CI -20.80 to -12.74) events/h (p<0.00001, I2 = 97%). The efficacy remained statistically different in the severity (AHI<30 or >30 events/h) and treatment duration (duration <5y or >5y) subgroups. Long-term use of MAD could also significantly decrease blood pressure and improve the score of functional outcomes of sleep questionnaire (FOSQ). Moderate evidence suggested that the subjective and objective effect of MAD on adult OSA has long-term stability. Limited evidence suggests long-term use of MAD might improve comorbidities and healthcare. In clinical practice, regular follow-up is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.